ECYT - The earnings call is next tuesday and an update on the EU application will be provided then. Ron Ellis, the CEO, seemed to indicate that the EU would encourage them to apply for accelerated approval. I think the disadvantage of choosing a select(FR++) population which would result in a shorter trial is that the EU may then ask endocyte to wait for the trial to complete or for an interim analysis before applying.
Market Data 
Markets 
AI
